Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data ImageneBio, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
9.19
31
15.6
9.16
3.5
0.8
Research and development
44.8
47.1
64.3
59.7
32.1
28.5
General and administrative
8.87
18
22.2
24.9
8.39
20.7
Operating expenses
53.7
65.1
86.5
84.6
40.5
49.3
Operating income
-44.5
-34.1
-70.9
-75.4
-37
-48.5
Interest income
0.02
2.15
7.11
Other non-operating income
0.26
0.02
2.14
7.09
0.45
2.75
Pre-tax income
-68.8
-68.3
-36.6
-45.7
Income tax
0
0
-0.16
0.01
-0.35
Net income
-44.3
-34.1
-68.8
-68.2
-36.6
-45.3
EBITDA
-44.2
-33.6
-70.2
-74.4
-35.9
-48.1
EPS, basic
-346.67
-26.43
-41.17
-35.32
-22.10
-9.64
EPS, diluted
-346.67
-26.43
-41.17
-35.32
-22.10
-9.64
Shares, basic (weighted)
0.13
1.29
1.67
1.93
1.19
4.87
Shares, diluted (weighted)
0.13
1.29
1.67
1.93
48.3
4.87
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
162
232
59.9
120
12.1
94.5
Short-term investments
97
55.6
0
40.8
Other current assets
1.54
0.63
0.96
1.15
0.35
4.94
Total current assets
166
237
160
179
12.5
140
Property, plant and equipment
1.39
2.44
3.21
2.34
0.01
0
Lease right-of-use assets
0.17
6.54
5.26
5.69
0.55
0.79
Other non-current assets
0.87
1.02
4.88
Total assets
168
248
172
192
15.9
153
Accounts payable
2.12
2.38
2.09
2.07
5.29
1.44
Accrued liabilities
1.82
2.81
3.24
3.31
0.93
2.89
Deferred revenue
20.6
17.1
9.16
0.65
0
Short-term debt
7.5
0
Total current liabilities
28.3
27.2
21.5
14.2
17.2
11.2
Lease liabilities
0
5.14
3.79
7.18
0.24
0.71
Other non-current liabilities
0.95
0
0.87
Total liabilities
63.5
40
25.3
22.3
17.4
19.8
Paid-in capital
10.3
353
362
452
2.16
363
Retained earnings
-111
-145
-214
-282
-180
-230
Other comprehensive income
-0.76
-0.05
-1.79
0.09
Shareholders' equity
-101
208
147
-126
-161
133
Total equity
-101
208
147
-126
-161
133
Total liabilities and equity
168
248
172
192
15.9
153
Shares outstanding
0.14
1.66
1.67
2.23
48.3
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-44.3
-34.1
-68.8
-68.2
-36.6
-45.3
Depreciation and amortization
0.3
0.54
0.75
1.02
1.1
0.4
Stock-based compensation
1.8
5.18
7.53
7.63
0
15.4
Deferred income tax
0
0
Change in payables
0.52
0.36
-0.29
-2.87
-0.52
-2.82
Cash from operations
-37.8
-60.3
-74.1
-79.7
-21.3
-47.8
Capital expenditures
-0.77
-1.76
-1.43
-0.41
Purchases of investments
-216
-90.1
0
-10.4
Sales and maturities of investments
118
155
10.2
9.8
Cash from investing
2.92
-1.76
-99.3
64.1
11.1
-5.81
Debt issued
7.5
15
Stock issued
0.07
0.58
1.1
37.4
0
0.05
Share buybacks
-0.66
Cash from financing
116
132
1.1
76
6.91
135
Exchange rate effect
0.09
0.6
Net change in cash
81.3
69.7
-172
60.4
-3.2
82.4
Free cash flow
-38.6
-62
-75.5
-80.2
Income taxes paid
0.22
0.02
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.72 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-36.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-34.5%
Net income / average total assets.
Return on invested capital (ROIC)
-98.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-77.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-62.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-38.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value CAGR, 3y
-3.2%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
860.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-3.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-1.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
-89.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
42.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
107.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
21.5x
Current assets / current liabilities.
Quick ratio
20.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
20.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$3.25
Cash from operations / diluted weighted shares.
Book value per share
$8.79
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.38x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.38x
Market cap / tangible book value, when positive.
Earnings yield
-98.0%
Net income / market cap (the inverse of P/E).
What was ImageneBio, Inc.'s revenue in fiscal 2025?
ImageneBio, Inc. reported revenue of $800.0K for fiscal 2025, 77.1% lower than the year before.
Was ImageneBio, Inc. profitable in fiscal 2025?
No. It reported a net loss of $45.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.